Applied Genetic Technologies Co. (NASDAQ:AGTC) Given Average Rating of “Moderate Buy” by Brokerages – Defense World
Posted by admin on Jul 24th, 2022 
Shares of Applied Genetic Technologies Co. (NASDAQ:AGTC – Get Rating) have received an average rating of “Moderate Buy” from the eight analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $15.00.
Several brokerages have weighed in on AGTC. Cantor Fitzgerald restated an “overweight” rating on shares of Applied Genetic Technologies in a research note on Tuesday, May 17th. Chardan Capital restated a “buy” rating on shares of Applied Genetic Technologies in a research note on Monday, April 11th. StockNews.com began coverage on Applied Genetic Technologies in a research note on Friday. They set a “sell” rating on the stock. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $10.00 target price on shares of Applied Genetic Technologies in a research note on Thursday, April 14th.
A number of hedge funds have recently made changes to their positions in AGTC. Kestra Advisory Services LLC bought a new stake in Applied Genetic Technologies in the 4th quarter valued at about $53,000. Renaissance Technologies LLC raised its stake in Applied Genetic Technologies by 33.8% in the 1st quarter. Renaissance Technologies LLC now owns 118,840 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 30,000 shares during the period. Shay Capital LLC bought a new stake in Applied Genetic Technologies in the 1st quarter valued at about $54,000. Virtu Financial LLC bought a new stake in Applied Genetic Technologies in the 1st quarter valued at about $75,000. Finally, Empery Asset Management LP bought a new stake in Applied Genetic Technologies in the 1st quarter valued at about $107,000. 38.03% of the stock is currently owned by institutional investors.
NASDAQ AGTC opened at $0.39 on Friday. The company has a current ratio of 2.73, a quick ratio of 2.73 and a debt-to-equity ratio of 0.24. The company has a fifty day simple moving average of $0.76 and a 200 day simple moving average of $1.26. Applied Genetic Technologies has a 12-month low of $0.35 and a 12-month high of $3.88. The company has a market cap of $19.59 million, a P/E ratio of -0.26 and a beta of 1.67.
Applied Genetic Technologies (NASDAQ:AGTC – Get Rating) last issued its quarterly earnings data on Monday, May 16th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.09. Sell-side analysts predict that Applied Genetic Technologies will post -1.49 earnings per share for the current fiscal year.
(Get Rating)
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials.
Receive News & Ratings for Applied Genetic Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Applied Genetic Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.
10,872 Shares in Cambria Emerging Shareholder Yield ETF (BATS:EYLD) Acquired by Kestra Advisory Services LLC
Comerica Bank Has $2.06 Million Stock Position in Cirrus Logic, Inc. (NASDAQ:CRUS)